We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

8 hedge funds and large institutions have $3.11M invested in Chemomab Therapeutics in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
+$1.58M
2
AIC
AWM Investment Company
New York
+$790K
3
RI
RTW Investments
New York
+$477K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$340K
5
DG
Delek Group
Israel
+$206K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Kennedy Capital Management
Missouri
$1.36M +$1.58M +3,125 New
AIC
2
AWM Investment Company
New York
$679K +$790K +1,563 New
RI
3
RTW Investments
New York
$411K +$477K +944 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$288K +$340K +672 New
MIH
5
Meitav Investment House
Israel
$177K +$206K +408 New
DG
6
Delek Group
Israel
$176K +$206K +408 New
UBS Group
7
UBS Group
Switzerland
$19K +$21.7K +43 New
CCA
8
Catalyst Capital Advisors
New York
$3K +$4.05K +8 New

CMMB Hedge Fund Activity: Q1 2019 in Review

8 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q1 2019, worth a combined $3.11M.

Buyers outnumbered sellers: 8 funds opened new CMMB positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.58M.

  • 8 institutional investors held Chemomab Therapeutics (CMMB) as of Q1 2019, up from 0 in Q4 2018.
  • Funds reported $3.11M of Chemomab Therapeutics stock for Q1 2019.
  • 8 funds opened new Chemomab Therapeutics positions in Q1 2019 and 0 closed out, a net change of +8 holders.
  • The largest Chemomab Therapeutics buyer in Q1 2019 was Kennedy Capital Management, an estimated $1.58M added.

Based on aggregated 13F filings for Q1 2019.